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Abstract
Background: There are limited treatment options that clinicians can provide to children presenting to emergency
departments with vomiting secondary to acute gastroenteritis. Based on evidence of effectiveness and safety,
clinicians now routinely administer ondansetron in the emergency department to promote oral rehydration therapy
success. However, clinicians are also increasingly providing multiple doses of ondansetron for home use, creating
unquantified cost and health system resource use implications without any evidence to support this expanding
practice.
Methods/design: DOSE-AGE is a randomized, placebo-controlled, double-blinded, six-center, pragmatic clinical trial
being conducted in six Canadian pediatric emergency departments (EDs). In September 2019 the study began
recruiting children aged 6months to 18 years with a minimum of three episodes of vomiting in the 24 h preceding
enrollment, <72 h of gastroenteritis symptoms and who were administered a dose of ondansetron during their ED
visit. We are recruiting 1030 children (1:1 allocation via an internet-based, third-party, randomization service) to
receive a 48-h supply (i.e., six doses) of ondansetron oral solution or placebo, administered on an as-needed basis.
All participants, caregivers and outcome assessors will be blinded to group assignment. Outcome data will be
collected by surveys administered to caregivers 24, 48 and 168 h following enrollment. The primary outcome is the
development of moderate-to-severe gastroenteritis in the 7 days following the ED visit as measured by a validated
clinical score (the Modified Vesikari Scale). Secondary outcomes include duration and frequency of vomiting and
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diarrhea, proportions of children experiencing unscheduled health care visits and intravenous rehydration, caregiver
satisfaction with treatment and safety. A preplanned economic evaluation will be conducted alongside the trial.
Discussion: Definitive data are lacking to guide the clinical use of post-ED visit multidose ondansetron in children
with acute gastroenteritis. Usage is increasing, despite the absence of supportive evidence. The incumbent
additional costs associated with use, and potential side effects such as diarrhea and repeat visits, create an urgent
need to evaluate the effect and safety of multiple doses of ondansetron in children focusing on post-emergency
department visit and patient-centered outcomes.
Trial Registration: ClinicalTrials.gov: NCT03851835. Registered on 22 February 2019.
Keywords: Ondansetron, Child, Vomiting, Gastroenteritis, Dehydration, Emergency service, hospital, Randomized
controlled trial
Background
The annual burden of acute gastroenteritis (AGE) in the
USA includes 17 million related episodes and 473,832
hospitalizations [1]. Although oral rehydration therapy is
recommended for children with mild-to-moderate dehy-
dration, it has historically been underused by emergency
department (ED) clinicians who are more likely to
choose intravenous over oral rehydration, especially
when vomiting is a major symptom [2]. Based on evi-
dence of efficacy, the antiemetic agent ondansetron is
frequently used to promote the success of oral rehydra-
tion therapy in children with vomiting secondary to
AGE [3, 4]. At present, more than 80% of physicians
routinely administer antiemetics to children who fail an
oral fluid challenge, regardless of specialty training and
practice location (i.e., community versus academic) [4].
Their use appears to be maximal (87%) among physi-
cians working in pediatric EDs [4].
A 2013 overview [5] identified four studies that evalu-
ated the efficacy of single-dose oral ondansetron com-
pared to placebo in children with gastroenteritis
presenting to an ED for medical care in high-income
countries. Ondansetron administration reduces hospital
admission and intravenous rehydration rates but has no
impact on ED revisits. However, among the subgroup of
children who did revisit an ED, those administered
ondansetron at the index visit were less likely to receive
intravenous rehydration at the revisit [5].
Although many studies have evaluated the use of
single-dose oral ondansetron, very few have focused on
the use of multiple doses. In 2002, Ramsook et al. [6]
conducted a single-center, double-blind, placebo-
controlled trial involving 145 children. They allocated
children to receive six doses of ondansetron versus pla-
cebo administered every 8 h for 2 days. In keeping with
other single-dose studies, vomiting was reduced after the
first dose; however, no benefits occurred following dis-
charge. At the 24- and 48-h follow-up time points, the
median number of vomiting episodes remained zero,
with no statistically significant difference between
groups. However, during the 48 h following ED dis-
charge, children administered ondansetron had threefold
more diarrheal episodes than those in the placebo group
(mean 7.7 versus 2.3) and a higher ED revisit rate (5%
versus 0%; P = 0.05).
In 2010, in the only other multidose study to date, Yil-
maz et al. conducted a randomized trial in Turkey [7].
They provided 109 participants with ondansetron or pla-
cebo every 8 h for 24 h. Although ondansetron adminis-
tration reduced the frequency of vomiting following
discharge (mean of 1.7 versus 0.2 episodes over 24 h;
P < 0.001), its administration was associated with a small
increase in the number of diarrheal episodes (5.0 versus
4.3 episodes; P = 0.04). There was no between-group dif-
ference with regards to ED return visits (ondansetron,
13%; placebo, 14%; P = 0.85).
The results of these clinical trials are conflicting and
limited. They focus on individual symptoms and out-
comes without enabling a proper assessment of overall
wellbeing. Nonetheless, multiple-dose ondansetron use
following ED discharge is on the rise. Between 2010 and
2015, 36% of nearly 12,000 children discharged from a
New York City pediatric ED with AGE were provided
with a prescription for home ondansetron use [8]. How-
ever, children prescribed ondansetron were equally likely
to revisit the ED (adjusted odds ratio 1.12, 95% confi-
dence interval 0.92–1.33) and be admitted at a revisit
(adjusted odds ratio 0.81, 95% confidence interval 0.51–
1.27). Similarly, in a study that included 996 children
with AGE treated in a pediatric ED in Minneapolis be-
tween 2012 and 2014, where 71% of eligible children
were discharged with prescriptions for ondansetron,
there were no reductions in 3- (5% in both groups; P =
0.75) and 7-day (6% among those provided with a pre-
scription versus 5% among those not provided a pre-
scription; P = 0.66) ED revisits [9].
Given the limited literature regarding multiple-dose
ondansetron use after ED discharge, the associated costs
to the health care system and families, and the potential
downsides of treatment, the proposed DOSE-AGE
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(multi-DOSE oral ondansetron for pediatric Acute
GastroEnteritis) comparative effectiveness study will in-




The provision of additional doses of ondansetron follow-
ing the administration of an initial dose in the ED will
be associated with improved outcomes compared with
the administration of a single dose of ondansetron
followed by a placebo in children aged 6 months to 18
years who present to a pediatric ED with ≥3 episodes of
vomiting due to AGE in the preceding 24 h.
Study questions
Clinical efficacy
Clinical efficacy will be determined by comparing the
following outcomes in the two study groups:
1. Is there a difference in the proportion of children
who develop moderate-to-severe disease (Modified
Vesikari Scale (MVS) score ≥9)?
2. Is there a difference in the: i) time until the last
vomiting episode after enrollment; ii) frequency of
vomiting; or iii) proportion who experience
vomiting?
3. Is there a difference in the proportion of children
who require an unscheduled health care provider
visit?
4. Is there a difference in the proportion of children
who require intravenous rehydration?
5. Is there a difference in satisfaction with care, as
reported by caregivers?
Safety
Do children with AGE-associated vomiting who are pro-
vided with additional doses of ondansetron for as-
needed home use following an initial dose in the ED ex-
perience adverse effects (e.g., increased number of diar-
rheal episodes, cardiac symptoms) compared to those
given a placebo?
Study design
DOSE-AGE is a randomized, placebo-controlled,
double-blinded, six-center, pragmatic clinical trial being
conducted in six Canadian pediatric EDs. We will
randomize 1030 children at a 1:1 ratio to receive either
48 h of ondansetron oral solution (0.15 mg/kg to a max-
imum single dose of 8 mg) [10] or a matching placebo to
be administered by the child’s caregiver as needed.
Ethics approval
Research Ethics Board (REB) approval has been granted
by the board of record at each participating study site:
Alberta Children’s Hospital/University of Calgary, Chil-
dren’s Hospital of Eastern Ontario, Centre Hospitalier
Universitaire Ste-Justine/Université de Montréal,
London Health Sciences Centre/Western University,
Stollery Children’s Hospital/University of Alberta, and
The Children’s Hospital of Winnipeg/University of
Manitoba. Following consultation with Health Canada, it
was determined that a Clinical Trials Application with
Health Canada’s Therapeutics Directorate was not re-
quired for this study.
Study population
The study population will consist of children aged 6
months to 18 years diagnosed as having an acute intes-
tinal infection by the ED treating physician and adminis-
tered ondansetron during their ED visit. The diagnosis
of an acute intestinal infection is at the discretion of the
treating ED physician. A range of terminologies that
may reflect an acute intestinal infectious process are ac-
ceptable provided they meet all other eligibility criteria
(e.g., viral illness, diarrhea, vomiting, upper respiratory
infection, postinfectious gastroenteritis, antibiotic-
associated diarrhea, toddler’s diarrhea, viral infection,
enteritis, viremia, fever and bronchiolitis) [11].
Inclusion criteria
All of the following criteria must be met for inclusion in
the study:
1. Aged 6 months to <18 years
2. Presence of ≥3 episodes of vomiting in the 24 h
preceding the ED visit
3. Duration of vomiting and diarrheal symptoms <72 h
4. Minimum of one episode of vomiting within 6 h of
eligibility screening
5. Minimum of one dose of ondansetron (oral or
intravenous) administered during the ED visit
Exclusion criteria
Individuals who meet any of the following criteria will
be excluded from participation in the study:
1. Bilious or bloody vomitus
2. Allergy to ondansetron or any serotonin receptor
antagonist
3. Known allergic reaction to components of
ondansetron or the placebo medication
4. History or family history of long-QT syndrome [12]
5. Presence of complex congenital heart disease
6. History or family history of cardiac arrhythmia
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7. History of glucose-6-phosphate dehydrogenase
deficiency
8. Concomitant use of any of the following:
a. QTc [12] prolonging medications (e.g.,
methadone, antidepressants, antiarrhythmics)
b. Medications known to cause torsades de pointes
(e.g., macrolide antibiotics, apo morphine)
c. Medications that cause electrolyte abnormalities
(e.g., high-dose corticosteroids, diuretics)
d. Serotonergic or neuroleptic medications (e.g.,
triptans, selective serotonin reuptake inhibitors,
serotonin norepinephrine reuptake inhibitors,
fentanyl, monoamine oxidase inhibitors, lithium)
e. Any 5-hydroxytryptamine (5-HT)3 receptor
antagonist excluding ondansetron
9. Inability to complete follow-up
10. Previously enrolled in study
Intervention
The schedule of activities is shown in Fig. 1. Participants
will be recruited from six Canadian EDs. Informed con-
sent and assent, as per local guidelines, will be obtained
from each participant and/or their legally authorized
representative prior to study enrollment. The process
includes approval for re-use of study data by approved
researchers who have their new study approved by an
ethics board and sign an agreement ensuring data confi-
dentiality and the restriction of use to only the approved
study.
Once consent has been obtained, the participant will
be allocated, by a web-based randomization service
(www.randomize.net) to receive either ondansetron oral
solution or a matched placebo. The study medication
dose will be 0.15 mg/kg, calculated using the partici-
pant’s weight as measured at the index ED visit. The
maximal single dose that can be provided is 8 mg, which
corresponds to 10 ml.
Caregivers will be instructed to administer a dose,
based on need as assessed by the caregiver (i.e., for pre-
verbal children) or expressed by the child (i.e., for verbal
children), every 8 h to a maximum of three doses in a
24-h period. A dose should only be administered if it is
felt the child is nauseated or experiencing ongoing
vomiting and hence would be beneficial. Caregivers will
be given a study medication diary to track the adminis-
tration of study medication doses and a discharge in-
struction sheet explaining the primary benefits of
medication use, how to contact the study team, study
Fig. 1 Schedule of activities. ED emergency department, HR heart rate, RR respiratory rate
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requirements, and health care provider follow-up cri-
teria. If admitted to hospital, participants will continue
on the study protocol. Enrolled children should not re-
ceive any nonstudy intervention doses of ondansetron
during the 48-h period following randomization.
Investigational agents
The active intervention administered is ondansetron 4
mg/5 ml oral solution (Zofran®; purchased from Sandoz
Canada, Novartis Pharmaceuticals). Ondansetron hydro-
chloride is a selective serotonin receptor antagonist of
the 5-HT3 subtype [13]. Its precise mode of action in the
control of nausea and vomiting is unknown. A placebo
solution, matched in taste, appearance, consistency and
smell, was developed by the College of Pharmacy, Uni-
versity of Manitoba. The study intervention is dosed at
0.15 mg/kg (0.1875ml/kg) to a maximum single dose of
8 mg [10]. Placebo stability testing was performed result-
ing in solution stability of 120 days from the compound
date. Kits will be replaced prior to the expiry date and
multiple batches will be employed at each study site.
Randomization
To ensure allocation concealment, an independent,
third-party web-based randomization service, www.
randomize.net, was used to produce the study treatment
allocation lists stratified by study site and weight (<20 kg
versus ≥20 kg). The treatment allocation list was sent to
the coordinating pharmacy at the Alberta Children’s
Hospital. The research pharmacy team at the Alberta
Children’s Hospital securely distributed the
randomization list to each study site pharmacy where
the study pharmacist prepared consecutively numbered
kits according to the randomization schedule. The avail-
able kits are stored in site pharmacies or in the enrolling
site’s ED. Kit inventory is temperature monitored and
securely stored.
Allocation concealment
The web-based randomization system, www.randomize.
net, utilizes industry-standard security to send data via
the internet. The randomization has been designed to
employ random blocks of 4 and 6 and to use a 1:1 allo-
cation ratio. Stratification by site and weight and block
randomization will ensure variables are comparably dis-
tributed across treatment arms. Randomize.net has the
advantage of assigning the subject to a kit ID number
during the actual randomization process (i.e., we will
employ remote computer subject randomization, kit IDs
are not sequentially assigned).
Unblinding should only occur when the treating phys-
ician and study investigator determine that knowledge of
treatment allocation will alter the clinical care being pro-
vided. Approval for unblinding must be obtained from
the principal investigator (SBF) or site investigator prior
to unblinding treatment. If the principal investigator
cannot be reached, in urgent situations unblinding can
be performed by the site investigator and the principal
investigator informed within 24 h via email or telephone
call.
Implementation
A log of all screened patients will be maintained. If eli-
gible, the details of the study will be discussed with the
caregiver and patient. Once consent has been obtained,
enrolled participants will be assigned a participant ID
number by the clinical site via the study’s secure web-
based software platform, REDCap (Research Electronic
Data Capture) [14, 15]. REDCap provides: 1) an intuitive
interface for validated data capture; 2) audit trails for
tracking data manipulation and export procedures; 3)
automated export procedures for seamless data down-
loads to common statistical packages; and 4) procedures
for data integration and interoperability with external
sources. Study staff will collect baseline demographic
variables, clinical values, and current illness history data
using direct data entry into REDCap via an electronic
tablet. Subsequently, the participant will be randomized
using www.randomize.net to obtain treatment allocation.
Bias
The ondansetron and placebo oral solution are identical
in appearance, consistency, taste, and smell. The solu-
tions are packaged in identical, labelled, amber-colored
glass bottles. Study staff, participants, caregivers, health
care providers, data collectors and data analysts will re-
main blinded to treatment allocation until the end of the
study. The trial was registered at www.clinicaltrials.gov
prior to study initiation.
Concomitant medications
Patients currently taking QTc-prolonging medications,
medications known to cause torsades de pointes, medi-
cations that cause electrolyte abnormalities, serotonergic
or neuroleptic medications, as well as any 5-HT3 recep-
tor antagonists will be excluded from the study [13]. The
use of concomitant medications is at the discretion of
the child’s treating physician; however, the administra-
tion of ondansetron after randomization is not permit-




The primary outcome is the development of moderate-
to-severe disease in the 7 days after the index ED visit as
measured by the MVS score (Table 1) [16, 17]. Despite
limited evidence describing the characteristics of the
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original 20-point Vesikari Score, it has been employed as
a dichotomous variable in many clinical studies [19, 20].
The score correlates with other meaningful measures
such as caregiver anxiety, helplessness, stress [21], par-
ental worry, behavioral changes and impact on the par-
ents’ daily activities and distress [22]. Challenges with
the use of the original score in large outpatient trials,
particularly with assessing percent dehydration—an
element of the original score [11]—led to the develop-
ment and validation of the MVS [16, 17]. The modified
score includes an important and easy to obtain outcome
that reflects global gastroenteritis disease severity: the
need for unscheduled health care provider visits. This is
supported by evidence that the utilization of professional
medical care correlates with disease severity [21]. Re-
cently, two large multicenter ED-based randomized con-
trolled trials have employed the MVS as a primary
outcome [23, 24].
Follow-up will occur, either by telephone or emailed
survey (to be selected by the participant), at 24, 48 and
168 h (i.e., 7 days) after the index visit. After follow-up
data have been collected, the MVS score will be calcu-
lated based on the information provided. Each variable
in the MVS is assigned a score for the entire study
period (time 0 to day 7), with each participant being
assigned a single score for the study period. Participants
are being asked to submit daily information (at 24 and
48 h) and then summative information (covering a 5-day
period) based on our extensive experience that such an
approach maximizes accuracy while minimizing burden
and conflicting data [23, 25, 26]. Variables are scored
based on the worst 24-h period (maximal frequency
components), on the total duration of symptoms (dur-
ation components, in hours), or on the occurrence of an
outcome (event components). While the data collected
at baseline will allow us to calculate an index visit (i.e.,
pre-enrollment) MVS score, all participant scores will
revert to 0 (i.e., no symptoms) following enrollment. The
pre-enrollment score will serve as a covariate in a regres-
sion analyses and will be employed for subgroup analysis
purposes. Only outcomes and symptoms that occur after
study enrollment will contribute to the calculation of the
primary outcome.
In the MVS derivation study [17], construct validity
was proven by using scores of ≥9 to define moderate
and ≥11 to define severe disease. These cut-off points
were associated with significant increases in other mea-
sures of disease severity (e.g., daycare absenteeism (P =
0.01) and work absenteeism (P = 0.002)) [17].
Secondary outcomes
1) Frequency of vomiting from study enrollment to
day 7. The total number of episodes of vomiting
and diarrhea related to the presenting illness will be
compared between groups. These data will be
obtained from the study questionnaires performed
at 24, 48 and 168 h after enrollment. Questionnaires
will contain questions regarding vomiting presence,
number of episodes and vomiting cessation date
and time. Frequency will be defined as the total
number of episodes across the study duration.
2) Duration of vomiting, defined as the total number
of days the participant experiences vomiting from
day 0 to day 7. These data will be obtained from
the study questionnaires performed at 24, 48 and
168 h after enrollment. A participant with a 24-h
break in symptoms will be assumed to have ceased
vomiting.
3) Any vomiting within 7 days of enrollment. The
proportion of participants will be determined using
data from the participant questionnaires performed
at 24, 48 and 168 h after enrollment.
Table 1 Modified Vesikari Scale scorea
Scale component Score
0 Points 1 Point 2 Points 3 Points
Diarrhea duration (h) 0 <96 96 to <120 ≥120
Maximum number of watery stools/24-h period 0 1–3 4–5 ≥6
Vomiting duration (h) 0 <24 24 to <48 ≥48
Maximum number of vomiting episodes/24-h period 0 1 2–4 ≥5
Maximum recorded rectal temperature (°C)b <37.0 37.0 to <38.5 38.5 to <39.0 ≥39.0
Unscheduled health care visit None NA Primary care Emergency department
Treatment None Rehydration with intravenous fluids Hospitalization NA
NA not applicable
aIn the Modified Vesikari Scale score, one variable (percent dehydration) in the original score was replaced with the variable of unscheduled health care visits to
better measure the effect of acute gastroenteritis in outpatients given that the ability to perform frequent in-person assessments in an outpatient cohort of
children can be challenging; scores range from 0 to 20, with higher scores indicating more severe disease; children with a score of 9 or more were considered to
have moderate-to-severe gastroenteritis [16, 17]
bTemperatures are adjusted for the location of measurement: 1.1°C was added to axillary temperatures and 0.6°C was added to oral temperatures [18]
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4) Proportion of participants who have an
unscheduled health care provider visit within 7 days
of enrollment. Return visits for unscheduled care to
a health care provider related to vomiting, diarrhea,
dehydration, fever, abdominal pain or fluid refusal
within 7 days, not including scheduled visits (e.g.,
reassessments, vaccinations, and so forth) will be
assessed using follow-up questionnaires at 24, 48
and 168 h after enrollment. Return-to-care data will
be confirmed by reviewing the participant’s hospital
chart. Not all data within a patient’s medical record
will be available to the research team; therefore, the
questionnaires will be the primary source of these
data.
5) Proportion of participants who require intravenous
rehydration. If the participant required an
unscheduled health care visit (see point 4 above),
the participant will be asked additional questions
related to intravenous insertion, treatment course
and disposition. Intravenous fluids administered at
the index visit will not be included as part of this
outcome.
6) Caregiver satisfaction as measured by a five-point
Likert scale in the 48 h following ED disposition.
Caregiver satisfaction with the therapy provided
(oral ondansetron or placebo) in the 48 h following
ED disposition will be measured using a five-point
Likert scale.
Safety outcomes
To determine if discharged children, with vomiting sec-
ondary to AGE who are administered ondansetron in
the ED with additional doses taken at home as needed,
are at increased risk of adverse events (AEs) compared
with those receiving placebo, groups will be compared
regarding the development of any side effects. We will
also specifically report the frequency of diarrheal epi-
sodes during the 48 h following ED disposition and the
maximal number of diarrheal episodes in a 24-h period
[6, 25].
Data retrieval
Study data will be collected at the following time points
using email or telephone communication:
1. Telephone and electronic survey communication
24, 48 and 168-h after the index visit. At the index
visit, caregivers will select their preferred method of
communication—email (electronic) or telephone.
Caregivers will be contacted as scheduled by the
identified method. Follow-up surveys will be
performed using a standardized data collection
form. Detailed questioning will follow positive
responses, especially as it relates to symptoms of
vomiting and diarrhea. Caregivers will report if, and
how many, doses of the study medication were
administered.
2. Medical chart review. Data regarding revisits,
intravenous hydration and hospitalization will be
verified by reviewing medical charts (electronic
and/or paper) of enrolled participants using each
study site’s medical record database.
Sample size estimates
The sample size estimate was based on the assessment
of the between-group difference in proportions of
children with a postrandomization score ≥9 on the
MVS. The adoption of multidose, post-ED ondanse-
tron use can be recommended if the proportion of
the primary outcome is significantly lower among
those who receive multidose ondansetron. Calcula-
tions were based on a two-sided α of 0.05 and power
of 0.90. The null hypothesis is H0 : PC − PI = 0, where
PI and PC are the outcome probabilities in the inter-
vention and control groups, respectively. The alterna-
tive hypothesis is H1 : PC − PI ≠ 0.
Our estimated event rate in the control group emerges
from the analysis of data from over 1000 children where
ondansetron home use was rare. Participants were
followed prospectively and approximately 30% of these
children experienced moderate-to-severe disease follow-
ing the index visit [27, 28]. Expert surveys have indicated
that an absolute risk reduction of 10% in the occurrence
of moderate-to-severe AGE following the index visit
would constitute a minimal clinically important differ-
ence [23]. Therefore, our sample size calculation as-
sumed a 30% event rate in the control group for which
we desire to detect an absolute beneficial treatment ef-
fect of 10% with 90% power. Using a two-sided type I
error of 0.05 and the hypothesized proportions yields a
required total sample size of 784 patients [29]. Our ex-
pected power, should we find different event rates in our
two groups, is displayed in Table 2.
Based on previous work by our group [23, 30, 31], we
assume a 10% loss to follow-up, 5% withdrawal, and 3%
drop-in rate (i.e., provision of ondansetron outside of




The screening population includes all patients who are
screened for eligibility into the trial, regardless of
randomization or treatment status. This population rep-
resents all patients who meet all inclusion criteria and
who are screened in real time by study staff at the par-
ticipating site. This population will be used for reporting
study flow as per CONSORT guidelines.
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Intention-to-treat population
The intention-to-treat (ITT) population includes all par-
ticipants who are randomized into the trial regardless of
adherence to the protocol, including, for example, par-
ticipants who receive no study drug. The ITT population
will be used for the primary efficacy analyses in the
study and the main efficacy analyses of secondary out-
comes. All analyses using the ITT population will be
based on each participant’s assigned treatment arm, re-
gardless of treatment actually received.
Safety analysis population
The safety analysis population will include a subset of
participants who received any doses of the study medica-
tions. A subanalysis will be performed including only
those who took three or more doses (the multidose
population) to assess the impact of multiple doses of
ondansetron on diarrhea and other safety outcomes.
Reporting of results will be summarized according to
treatment received. This population will be used for ana-
lysis of AEs to examine safety outcomes.
Statistical analysis
All analyses will be completed using the ITT principle.
AEs will use the ‘as-treated’ principle and a secondary
safety analyses will employ the safety analysis population.
All statistical tests will be two sided with significance de-
clared at the 0.05 level. The family-wise error rate will
be controlled for secondary outcomes using the Holm
stepdown procedure [32]. All outcomes and baseline
characteristics will be reported by study group, using fre-
quency counts and percentages for discrete variables,
and means, medians, standard deviations and interquar-
tile ranges for continuous variables. A detailed statistical
analysis plan is being concurrently published.
The primary analysis of the primary outcome will
compare the proportion of children who develop
moderate-to-severe disease utilizing a Mantel–Haenszel
test, stratified by clinical center and weight category. For
this analysis, we will report the absolute risk difference
and the Mantel–Haenszel test statistic, alongside 95%
confidence intervals. The secondary outcomes vomiting
duration and frequency, proportion with vomiting, un-
scheduled health care provider visits, intravenous rehy-
dration and caregiver satisfaction will be tested for
between-group differences using appropriate tests. An
additional exploratory analysis will assess the effects of
treatment after adjusting for baseline covariates.
Safety
The proportion of children experiencing AEs, an aggre-
gate outcome across all AEs, as reported by the care-
givers, will be compared between groups using the
Mantel–Haenszel test, stratified by site and weight
strata. A secondary analysis will assess AEs in the multi-
dose population. The frequency of diarrheal episodes
during the 48 h following the index visit and the max-
imal number of diarrheal episodes in a 24-h period will
be subject to statistical testing. No adjustment for multi-
plicity will be performed. Specific symptoms (e.g., palpi-
tations, syncope) will be reported in frequencies by
group and not subjected to hypothesis testing.
Planned subgroup analyses
The following prespecified subgroup analyses of the pri-
mary outcome will be performed:
1. Sex: male, female
2. Age: 6 months to <3.0 years, 3.0 to <6.0 years, 6.0 to
<10.0 years, and ≥10.0 years
3. Vomiting frequency: ≤10 versus >10 episodes in the
24 h preceding study enrollment
4. Presence of diarrhea in 24 h preceding enrollment:
yes, no
A subgroup effect will be declared significant if the
interaction between treatment and the subgroup factor
is significant in the appropriate statistical model for each
interaction at a significance level of 0.05/4 = 0.0125.
Data access
All deidentified individual participant data (including
data dictionaries) will be made available immediately fol-
lowing publication with no end date to investigators
whose proposed use of the data has been approved by
an independent review committee identified for this pur-
pose. Additional documents that will be available include
the study protocol, statistical analysis plan and the in-
formed consent forms. Proposals should be directed to
stephen.freedman@ahs.ca. To gain access; data re-
questors will need to sign a data access agreement.
Table 2 Power table based on 784 randomized children
completing follow-up
Outcome control Outcome intervention % Difference Power
0.25 0.15 0.10 0.94
0.25 0.20 0.05 0.39
0.25 0.25 0.00 NA
0.30 0.15 0.15 0.999
0.30 0.25 0.05 0.35
0.35 0.15 0.20 ~1
0.35 0.20 0.15 0.997
0.35 0.25 0.10 0.86
NA not applicable
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Safety
Safety oversight will be under the direction of the Data
and Safety Monitoring Board (DSMB), which is com-
posed of individuals with expertise in pediatric emer-
gency medicine, trial methodology and biostatistics.
DSMB members include Drs Garth Meckler (Chair,
Vancouver, Canada), Mark Roback (Minneapolis, USA),
Anupam Kharbanda (Minneapolis, USA), Eyal Cohen
(Toronto, Canada) and Lise Nigrovic (Boston, USA).
Meetings will be held biannually and on an ad hoc basis.
The DSMB has had initial meetings and reviewed and
approved the study protocol and monitoring plan; no in-
terim analyses are currently requested by the DSMB.
Should an interim analysis be required, it will be com-
pleted in accordance with the DSMB charter under the
direction of the chair. Appropriate adjustments to the
statistical analysis plan and significance level will be
made if performed. Any analyses that are undertaken
will be partially blinded with biostatisticians aware of
the treatment arm but not the associated identifier
(i.e., active or placebo). All by-treatment interim ana-
lyses will refer to arms as “A” and “B” throughout
analysis and reporting to the study team and DSMB.
The DSMB has the option to unblind treatment at
any time should they deem it necessary. Early stop-
ping for efficacy and futility will not be considered
due to concerns for overestimating or underestimating
treatment effects [33, 34].
Safety outcomes will be obtained via participant
follow-up questionnaires performed 24, 48 and 168 h
after enrollment. Summaries of incidence rates, intensity
and relationship to study by system organ class and pre-
ferred term (MedDRA) [35] will be prepared and re-
ported to the DSMB. All AEs beginning after
randomization will be included.
An AE has been defined as any adverse occurrence in
the health of a clinical trial participant which may or
may not be caused by the administration of the study
drug during the study period. Disease-related events are
expected events considered to be part of the natural his-
tory of the underlying disease process of AGE and will
not be reported as AEs. We have defined the following
as disease-related events:
1. Hospitalization for intravenous rehydration or
gastroenteritis-like symptoms
2. Future health care provider visits, including ED
return visit for vomiting, diarrhea or dehydration
3. Intravenous rehydration
4. Abdominal pain, distention, bloating
5. Vomiting, diarrhea, fever, flatulence
Additionally, any symptom or sign that was present
prior to randomization and that has not worsened since
participation in the study began will not be reported as
an AE.
Any serious adverse events (SAEs) that occur after
randomization will be reported to the REB as appropri-
ate and the study participant will be followed until satis-
factory resolution or until the site investigator deems the
event to be chronic or the participant is stable. An SAE
has been defined as any of the following:
1. Medically significant; based upon appropriate
medical judgment, the event may jeopardize the
patient and may require medical or surgical
intervention to prevent one of the other SAE-
defined outcomes.
2. Congenital malformation or birth defect
3. Persistent or significant disability or incapacity
4. Life threatening; an event in which the patient was
at immediate risk of death
5. Death
Participants may be withdrawn from the study by the
site or principal investigator for the following reasons:
1. If any clinical AE, laboratory abnormality or other
medical condition or situation occurs such that
continued participation in the study would not be
in the best interests of the participant
2. If the participant meets an exclusion criterion that
precludes further study participation (e.g., safety
concerns).
3. The participant’s caregiver wishes to withdraw their
child for whatever reason.
Discontinuation from the study intervention does not
indicate discontinuation from the study. Because care-
givers will administer the study intervention on an as-
needed basis, the study intervention may be discontin-
ued at any time by the caregiver. It is not mandatory to
administer all doses provided; therefore, the study proto-
col will not change unless discontinuation is due to an
AE.
Ancillary and post-trial care
No provisions have been made to provide ancillary,
post-trial care or compensation to those who suffer
harm from trial participation.
Health economic analysis
An analysis of the cost effectiveness of multidose oral
ondansetron will be undertaken to assess whether the
intervention presents value for money as well as clinical
effectiveness. A trial-based economic evaluation will be
conducted and will conform to guidelines for economic
evaluation from the Canadian Agency for Drugs and
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Technologies in Health [36]. The reference case will use
a publicly funded health care payer perspective, with pa-
tient and societal costs considered in secondary analyses.
The time horizon will be the first 7 days following dis-
charge from the ED, as differences are only expected
over this short time period.
Cost components in the reference case analysis will
consist of the number of doses of ondansetron provided
during presentation at the ED, admission to hospital or
use of intravenous hydration after presentation at the
ED, and use of other health services (e.g., family doctor,
revisit to ED, hospital admission) within 7 days of enroll-
ment. Additional cost components that will inform the
patient and societal perspective analyses will include the
number of doses of ondansetron provided under pre-
scription, drug insurance coverage, transport and child
care associated with health care use, and caregiver prod-
uctivity losses. Health utilities will not be collected as
many participants will be under 24 months of age and
no reliable instruments are available for populations of
this age. Due to this, the primary outcome of the trial,
the MVS score, will be used as the primary outcome in
the economic analyses.
Cost and outcome data will be combined to calculate
an incremental cost-effectiveness ratio and a net monet-
ary benefit statistic for the reference case and other ana-
lyses. A nonparametric bootstrapping approach will then
be used to determine uncertainty surrounding point esti-
mates and cost-effectiveness acceptability curves will be
generated to communicate the likelihood that interven-
tions are cost effective at a range of thresholds. If suffi-
cient data are available, subgroup analysis will examine
how cost effectiveness varies based on sex, age, and
vomiting and diarrhea frequency in the 24 h before ED
presentation.
Discrete choice experiment and caregiver preferences for
treatment outcomes
In conjunction with the pragmatic randomized con-
trolled trial, a discrete choice experiment (DCE) will be
conducted to examine caregiver preferences for different
outcomes during treatment of AGE and the impact of
this on the trial findings. The DCE approach asks partic-
ipants to choose or trade-off between different scenarios
with varying characteristics and, in doing so, allows esti-
mation of the relative importance of different character-
istics and, through that, their preferences to achieve
differing treatment outcomes [37]. The DCE in this pro-
ject will focus on the MVS score [16, 17] as the primary
outcome measure in the trial, and will ask participants
to make a series of choices between scenarios based on
possible outcomes from the MVS score. This will allow
an assessment of caregivers’ preferences for differing
outcomes and whether the current scoring approach for
the measure reflects these preferences for the disparate
components of the measure. This can inform discussions
about whether a different weighting system should be
considered and can examine whether the trial would re-
turn different conclusions if this novel scoring approach
was used.
To do this, the components included in the MVS will
be translated into attributes within the DCE (e.g., vomit-
ing duration, maximum number of vomiting episodes
per 24-h period) and the possible scores within each
component will be translated into levels within the DCE
(e.g., 1 to 24 h; 2 to 4 episodes). An experimental design
using these attributes and levels will then be generated
according to principles of statistical efficiency, while bal-
ancing this with the need to censor illogical combina-
tions and provide computational efficiency for
participants. The DCE will be embedded in a wider
questionnaire including sociodemographic information,
access to health care, and previous experiences with
AGE and, after piloting, will be distributed to an existing
cohort of caregivers of children with AGE who provided
permission to be contacted to participate in additional
research studies [38]. In the questionnaire, respondents
will choose between a series of choice sets which present
possible treatment outcomes with differing characteris-
tics across the included attributes and levels.
A multinomial logit model will be used to estimate
average preferences across the sample as a whole. If a
sufficient sample size is available, mixed multinomial
logit models will be used to assess heterogeneity of pref-
erences, which may highlight differences between sub-
groups within the sample. Descriptive characteristics of
the sample will be reported and the results of the DCE
analysis will be expressed as utility coefficients, and these
coefficients will be used to calculate a DCE-derived
weighting system for the components contained within
the MVS. This novel DCE-derived weighting system will
then be used to conduct exploratory analyses, and the
primary analyses of the DOSE-AGE trial will be repli-
cated with this scoring system. The results of these ex-
ploratory analyses will be compared with the primary
analysis described above to examine whether consider-
ation of caregiver preferences has an impact on the find-
ings of the trial. It is important, however, to be clear that
a novel weighting system would need consultation with
clinicians and further validation, and the exploratory
analyses will not supersede the main analyses from the
trial.
Trial management
Data collection and entry is the responsibility of the clin-
ical trials staff at the study site. Site investigators are re-
sponsible for ensuring accuracy and completeness of
reporting. The Women and Children’s Health Research
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Institute (University of Alberta, Edmonton, Canada) will
act as the data coordinating center (DCC) housing all
study data and will be responsible for the provision of
data collection tools and clinical data management ser-
vices. The methodology core (University of Toronto, To-
ronto, Canada), led by AH and PP, will be responsible
for data analyses as outlined in the published study stat-
istical analysis plan. SBF takes overall responsibility for
the DOSE-AGE study. Study data monitoring will be
performed by the University of Alberta Quality Manage-
ment in Clinical Research group after the first patient
has been enrolled at each site and every 6 months there-
after. The DCC and Quality Management in Clinical Re-
search group will actively monitor study data remotely.
This study is part of a collaborative approach to enable
the conduct of pediatric clinical research in Canada.
Under the KidsCAN-PERC Innovative Pediatrics Clinical
Trials initiative [39], four separate clinical trials will be
implemented sharing common resources and infrastruc-
ture. The DOSE-AGE steering committee is chaired by
TK and includes other members of the KidsCAN-PERC
Innovative Pediatrics Clinical Trials initiative.
Dissemination policy
All results from the study, be they positive, negative or
inconclusive, will be published in international scientific
journals. The project leader will enforce publication.
Furthermore, the results will be presented at national
and international conferences. Additionally, the results
of this study will be communicated directly to the partic-
ipants and to the public in general through the daily
press and social media.
Protocol amendments
Any modifications to the protocol that may impact on
the conduct of the study, potential benefit of the patient
or may affect patient safety, including changes of study
objectives, study design, patient population, sample sizes,
study procedures or significant administrative aspects,
will require a formal amendment to the protocol. Such
an amendment will be approved by the relevant REBs
prior to implementation. All participating sites will be
notified of all amendments via email and during monthly
team meetings. The principal investigator and/or his del-
egates assume responsibility for updating all relevant
stakeholders.
Confidentiality
Participant confidentiality and privacy are strictly held in
trust by the participating investigators, their staff and
the sponsor. This confidentiality is extended to cover the
clinical information relating to participants. Therefore,
the study protocol, documentation, data and all other in-
formation generated will be held in strict confidence. No
information concerning the study or the data will be re-
leased to any unauthorized third party without the prior
written approval of the sponsor.
All research activities will be conducted in as private a
setting as possible. The study monitor, other authorized
representatives of the sponsor, representatives of the
REB or regulatory agencies may inspect all documents
and records required to be maintained by the investiga-
tor, including, but not limited to, medical records and
pharmacy records for the participants in this study. The
clinical study site will permit access to such records.
The study participant’s contact information will be se-
curely stored at each clinical site for internal use during
the study. At the end of the study, all records will con-
tinue to be kept in a secure location for as long a period
as dictated by the reviewing REB, institutional policies or
sponsor requirements.
Study participant research data, which are for purposes
of statistical analysis and scientific reporting, will be
stored in the REDCap electronic data capture system at
the Women and Children’s Health Research Institute
(WCHRI) DCC at the University of Alberta. These data
will not generally include the participant’s contact or
identifying information. Rather, individual participants
and their research data will be identified by a unique
study identification number. Permission to store data at
the WCHRI DCC is included in the informed consent.
WCHRI’s REDCap installation is housed in a secure
data center at the University of Alberta Hospital and is
behind the Faculty of Medicine & Dentistry’s firewall.
Data is entered through a web-based interface using
128-bit SSL encryption. Login is via a username/pass-
word pair with additional two-factor authentication.
Additional information is available in WCHRI’s privacy
document (https://redcap.ualberta.ca/privacy.pdf).
Coordinators and investigators at each study site only
have access to data relating to their own study partici-
pants. Study management at the lead site and WCHRI
DCC staff have access to data for all study participants.
This access is required to perform system management
functions, data cleaning and analysis. Once the study
database is locked and data has been extracted for ana-
lysis, read-only access to the study database will be
granted to the principal investigator and/or their desig-
nate if requested.
Participant contact information is stored in the RED-
Cap data capture system for the purposes of follow-up
contact via email. The participant’s sex, date of birth,
weight and date of ED visit are also stored in the RED-
Cap database for the purposes of return visit validation,
chart reviews, accurate age and study medication dose
calculations. Participants/caregivers are informed of data
collection and storage policies during the informed con-
sent process.
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Discussion
All investigators involved in the study have acknowl-
edged a position of equipoise in relation to the discharge
antiemetic management of children with AGE-
associated vomiting; they accept that there is currently
insufficient robust clinical evidence defining the optimal
use of ondansetron in this group of children.
This study aims to evaluate the provision, at discharge,
of additional doses of ondansetron to children who have
already received an initial dose of ondansetron in the ED
as part of their standard care for AGE-associated vomit-
ing. It is recognized that there is heterogeneity within
the pediatric emergency medicine community regarding
the use of post-ED ondansetron. This study will contrib-
ute to the understanding of the optimal treatment ap-
proach to children with AGE-associated vomiting who
seek ED care.
The trial-based economic evaluation will allow an
examination of the cost effectiveness of the use of post-
ED ondansetron and will inform discussions on whether
this adaptation to care provides value for money. Finally,
the DCE conducted alongside the trial will allow an
examination of caregivers’ preferences for differing treat-
ment outcomes after presentation at the ED for AGE-
associated vomiting. This will allow an assessment of
whether the scoring approach used as the primary out-
come measure of the trial reflects differing preference
weights assigned to outcomes within the measure and
will also provide a wider consideration of whether
changes to management of AGE-associated vomiting are
aligned with caregiver preferences and whether scoring a
measure according to caregiver preferences alters the
findings of the trial.
Trial status
As of 29 February 2020, 132 children have been enrolled
at the six study sites. The current protocol version is 3.0.
Anticipated completion of recruitment is 31 May 2022.
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